CMS Dashes Industry Hopes For MCIT Rule Any Time Soon

The US Medicare agency has proposed to withdraw a rule that would give temporary automatic coverage to breakthrough devices, stating the rule doesn’t meet its evidence threshold and could put patients at risk.­­­­­­­

zoomed stop sign at night on lonely road

The Biden administration has put the kibosh on a highly anticipated rule that would’ve given immediate Medicare coverage to breakthrough medical devices. The US Centers for Medicare and Medicaid Services (CMS) says as it stands, the rule would require reimbursement for products not proven to work in patients 65 and older, and for that reason it’s proposing to stop the rule from going into effect.

The Medicare Coverage for Innovative Technologies (MCIT) rule has been touted by industry and other proponents as a critical step to bringing new treatments to elderly patients faster. They have long argued that after the Food and Drug Administration allows a new product on the market under its expedited breakthrough devices program, it can take years to aggregate product data that satisfies the Medicare agency’s reimbursement evidence requirements

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

Faster Device Certification Among Keys To Unlocking Innovation In EU MedTech Sector

 

While MedTech Europe sharpens its focus on what the EU most urgently needs to advance the medtech market in four targeted measures, the European Commission has also unveiled four priorities for 2025.

MedTech Europe’s Bisazza Urges Action As US Tariffs Jeopardize Critical Global Supply Chains

 

The intricate assembly of medical devices, often involving over 1,000 globally sourced components, faces severe disruption due to new US tariffs. These barriers could halt production and devastate small and medium-sized enterprises (SMEs), MedTech Europe’s CEO, Oliver Bisazza, warns in an interview with Medtech Insight.

FDA Announces Classifications On 9 Device Types

 
• By 

The US Food and Drug Administration has announced new classifications for eight device types that reached market via the de novo process, with most of the newly classified products in the diagnostics sector.

Medical Devices Not The Focus Of FDA’s Plans To Step Up Foreign Inspections, Expert Says

 

The US FDA recently announced plans to carry out more unannounced inspections of foreign facilities. But those inspections will primarily target drug producers, with less attention and resources allocated to those making devices.

More from Policy & Regulation

Beyond The Bladder: Incontinence Impacts Mental Health

 

In recognition of Mental Health Awareness month, Sarah Jenkins, executive director at the National Association for Continence, discussed the mental health issues that often come with incontinence.

AI Rollout Aims To Accelerate FDA’s Product Review Process

 
• By 

The FDA plans to implement artificial intelligence in its scientific review process by 30 June, following a successful pilot. The agency hopes the tool will reduce nonproductive tasks for reviewers amid recent staff cuts. A Chief AI Officer will oversee the rollout and integration.

Access To Library Tools Being Restored At US FDA

 

Agency staff once again have access to the Lexis-Nexis legal and news database, but are still waiting for access to journals and laid off librarians have not been reinstated.